Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitotic spindle organizing protein 2A (MZT2A) is a centrosomal protein that localizes at the centrosome and is a component of the γ-tubulin ring complex (γ-TuRC), essential for microtubule nucleation and mitotic spindle formation during cell division[2][3][6]. It regulates the balance of microtubule polymerization and depolymerization in the centrosome, ensuring proper mitosis and cell proliferation[2]. MZT2A is overexpressed in certain cancers, such as non–small cell lung cancer, where its elevated activity is associated with tumor growth and poor prognosis[2]. Loss of MZT2A disrupts microtubule nucleation, slows cell proliferation, and can impair faithful chromosome segregation[2][3]. MZT2A is also known as GCP8a, FAM128A, and MOZART2[2][3]. There are currently no drugs or established mechanisms of action specifically targeting MZT2A reported in the available literature[2]. However, its role in cancer highlights its potential both as a therapeutic target and as a biomarker for disease monitoring[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitotic spindle organizing protein 2A (MZT2A).